RT Journal Article
SR Electronic
T1 An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.09.21253218
DO 10.1101/2021.03.09.21253218
A1 Lumley, Sheila F
A1 Rodger, Gillian
A1 Constantinides, Bede
A1 Sanderson, Nicholas
A1 Chau, Kevin K
A1 Street, Teresa L
A1 O’Donnell, Denise
A1 Howarth, Alison
A1 Hatch, Stephanie B
A1 Marsden, Brian D
A1 Cox, Stuart
A1 James, Tim
A1 Warren, Fiona
A1 Peck, Liam J
A1 Ritter, Thomas G
A1 de Toledo, Zoe
A1 Warren, Laura
A1 Axten, David
A1 Cornall, Richard J
A1 Jones, E Yvonne
A1 Stuart, David I
A1 Screaton, Gavin
A1 Ebner, Daniel
A1 Hoosdally, Sarah
A1 Chand, Meera
A1 ,
A1 Crook, Derrick W
A1 O’Donnell, Anne-Marie
A1 Conlon, Christopher P
A1 Pouwels, Koen B
A1 Walker, A Sarah
A1 Peto, Tim EA
A1 Hopkins, Susan
A1 Walker, Timothy M
A1 Stoesser, Nicole E
A1 Matthews, Philippa C
A1 Jeffery, Katie
A1 Eyre, David W
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.09.21253218.abstract
AB Background Natural and vaccine-induced immunity will play a key role in controlling the SARS-CoV-2 pandemic. SARS-CoV-2 variants have the potential to evade natural and vaccine-induced immunity.Methods In a longitudinal cohort study of healthcare workers (HCWs) in Oxfordshire, UK, we investigated the protection from symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infection conferred by vaccination (Pfizer-BioNTech BNT162b2, Oxford-AstraZeneca ChAdOx1 nCOV-19) and prior infection (determined using anti-spike antibody status), using Poisson regression adjusted for age, sex, temporal changes in incidence and role. We estimated protection conferred after one versus two vaccinations and from infections with the B.1.1.7 variant identified using whole genome sequencing.Results 13,109 HCWs participated; 8285 received the Pfizer-BioNTech vaccine (1407 two doses) and 2738 the Oxford-AstraZeneca vaccine (49 two doses). Compared to unvaccinated seronegative HCWs, natural immunity and two vaccination doses provided similar protection against symptomatic infection: no HCW vaccinated twice had symptomatic infection, and incidence was 98% lower in seropositive HCWs (adjusted incidence rate ratio 0.02 [95%CI <0.01-0.18]). Two vaccine doses or seropositivity reduced the incidence of any PCR-positive result with or without symptoms by 90% (0.10 [0.02-0.38]) and 85% (0.15 [0.08-0.26]) respectively. Single-dose vaccination reduced the incidence of symptomatic infection by 67% (0.33 [0.21-0.52]) and any PCR-positive result by 64% (0.36 [0.26-0.50]). There was no evidence of differences in immunity induced by natural infection and vaccination for infections with S-gene target failure and B.1.1.7.Conclusion Natural infection resulting in detectable anti-spike antibodies and two vaccine doses both provide robust protection against SARS-CoV-2 infection, including against the B.1.1.7 variant.Summary Natural infection resulting in detectable anti-spike antibodies and two vaccine doses both provided ≥ 85% protection against symptomatic and asymptomatic SARS-CoV-2 infection in healthcare workers, including against the B.1.1.7 variant. Single dose vaccination reduced symptomatic infection by 67%.Competing Interest StatementDWE declares lecture fees from Gilead, outside the submitted work. RJC is a founder shareholder and consultant to MIROBio, outside the submitted work. No other author has a conflict of interest to declare.Funding StatementThis work was supported by the UK Government's Department of Health and Social Care. This work was also supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with Public Health England (PHE) (NIHR200915), the NIHR Biomedical Research Centre, Oxford, and benefactions from the Huo Family Foundation and Andrew Spokes. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health or Public Health England. This study is affiliated with Public Health England's SARS-CoV-2 Immunity & Reinfection EvaluatioN (SIREN) study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Deidentified data were obtained from the Infections in Oxfordshire Research Database which has generic Research Ethics Committee, Health Research Authority and Confidentiality Advisory Group approvals (19/SC/0403, 19/CAG/0144).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed during the current study are not publicly available as they contain personal data but are available from the Infections in Oxfordshire Research Database (https://oxfordbrc.nihr.ac.uk/research-themes-overview/antimicrobial-resistance-and-modernising-microbiology/infections-in-oxfordshire-research-database-iord/), subject to an application and research proposal meeting the ethical and governance requirements of the Database. Sequence data generated during the study are available from the European Nucleotide Archive under study accession number PRJEB43319.